Zevra Therapeutics, Inc. Finance Lease, Liability, to be Paid, Year Five
Zevra Therapeutics, Inc. (ZVRA) had Finance Lease, Liability, to be Paid, Year Five of $0 as of 2022-12-31, per its 10-K filed 2023-03-07.
Discontinued › Notes › Finance Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive · last filed 2023-03-07
- 2022-12-31: Finance Lease, Liability, to be Paid, Year Five $0.00.
- 2021-12-31: Finance Lease, Liability, to be Paid, Year Five $0.00.
| Period end | Finance Lease, Liability, to be Paid, Year Five |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-07 |
| 2021-12-31 | $0.00 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |